Sign Up For Our Free Newsletter
Client Login

Billy Wynne J.D.

CEO and Founder

(202) 309-0796
billy@wynnehealth.com

Billy Wynne is the Founder and CEO of the Wynne Health Group, a consulting and advocacy firm serving Fortune 500 companies, marquee health systems and providers, life sciences manufacturers, health plans, foundations, and investment firms.

 

Prior to launching Wynne Health, Billy built and was Managing Partner of one of Washington’s leading health policy practices. He also designed and manages the most comprehensive online aggregator of health policy analysis – Policy Hub. He is a frequent commentator on cable news and is often quoted by leading Washington publications such as Politico and Inside Health Policy for insight into Federal health care-related developments.

 

From 2006 to 2008, Billy served as Health Policy Counsel to the Senate Finance Committee. In that capacity, he advised Committee Members on key health care policy matters, including Medicare, Medicaid and broader health care reform. Mr. Wynne was a key drafter and negotiator of several healthcare laws and assisted in the development of the healthcare reform “White Papers” that served as the basis for the Affordable Care Act.

 

Billy received a bachelor’s degree in Government from Dartmouth College and a law degree from the University of Virginia. He is a member of the District of Columbia and Virginia bar associations and serves on the boards of Operation Smile, Chinese Children Adoption International, and 9Health Services, which he chairs.

 

When he’s not working in Washington, Mr. Wynne lives in Denver, CO with his wife, Christy, and their children, Eleanor and Lei.

Education:

A.B., Dartmouth College; J.D., University of Virginia

Publications

The Drug Pricing Debate: Sizing Up Recent Actions and What May Come Next

By Billy Wynne and Josh LaRosa | March 7, 2019
What goes up must — or rather, should — come down. Such is the thinking of the Trump administration when it comes to prescription drug pricing, at least. Over the past five years, 12 of the 20 most commonly prescribed brand-name drugs have seen price increases of more than 50 percent. To date, most of what we’ve seen from the federal government is messaging and some initial proposals, with the majority coming from the administration. Congress, for its part, has initiated a series of drug pricing hearings and begun introducing meaningful legislation. The result is a wide array of policy alternatives, some of which stand a chance of being enacted....
+ Read More

Medicare For All Can Begin In 2021: Here’s How

By Billy Wynne and Alyssa Llamas | February 28, 2019
While Democratic presidential candidates and the newspaper headlines hash out the ideological nuances of a Medicare-based single payer coverage scheme, work is underway to consider how coverage can be expanded to those in need within a realistic timeframe at minimal cost or disruption to the existing system....
+ Read More

What to Expect in Health Policy Under a Divided Congress

By Billy Wynne and Dawn Joyce | January 8, 2019
The 2018 midterm elections were powered by a “blue wave” that flipped control of the House of Representatives from the GOP to the Democrats but left the Senate in Republican hands, meaning the two chambers of Congress will be divided at least until 2020. In the Senate, Republicans have a 53 to 47 majority and will continue to be led by Senator Mitch McConnell of Kentucky, while House Democrats gained a 235 to 199 majority....
+ Read More

What the 2018 Midterm Elections Means for Health Care

By Billy Wynne | November 7, 2018
The fundamental shift in the balance of power in Washington will have substantial implications for health care policymaking over the next two years. In this post, I’ll take a look at which health care issues will come to the fore of the Federal agenda due to the outcome Tuesday, as well as state expansion decisions. And it should of course be noted that, in addition to positive changes Democrats are likely to pursue over the next two years, House control will allow them to block legislation they oppose, notably further GOP efforts to repeal the Affordable Care Act (ACA)....
+ Read More

The 660-Page Opioids Bill Is Now the Law. Here’s What’s in It.

By Billy Wynne and Dawn Joyce | November 1, 2018
Opioids killed an estimated 49,000 Americans in 2017, including nearly 2,200 Californians. They harmed many more, including children forced into the foster care system, babies born with neonatal abstinence syndrome, young adults who overdosed from dangerous new street drugs like fentanyl, and countless others who became addicted to opioids while trying to manage chronic pain....
+ Read More

Immigrants and the New Proposed “Public Charge” Rule

By Billy Wynne & Dawn Joyce | October 2, 2018
On September 22, the Department of Homeland Security (DHS) released the text of highly anticipated proposed changes to “public charge” rules that could disqualify many immigrants from gaining permanent residency in the US. Public charge is the determination that evaluates whether someone is likely to become reliant on public benefits, and consequently whether he or she may enter the country or modify his or her immigration status to become a permanent resident (a “green card” holder). ...
+ Read More

Creating Medicare Advantage Premium Support For All, Part 5: Which Proposal Is Actually Medicare?

By Billy Wynne | August 15, 2018
With the burgeoning debate around single payer, primarily oriented around "Medicare for All," CEO Billy Wynne takes a look under the hood of Sen. Bernie Sanders' "M4All" proposal and discovers it is not actually based on Medicare. He also continues his inquiry into what bona fide Medicare for All would actually look like, in this case by explaining the basics of the Medicare Advantage program, which covers 33% of Medicare enrollees this year....
+ Read More

What Might Happen in Federal Health Policy Before the Midterm Elections

By Billy Wynne & Dawn Joyce | August 14, 2018
An in-depth guide to the key health policy issues that will dominate DC through the midterm elections....
+ Read More

Here’s What the House Passed to Tackle the Opioid Crisis

By Billy Wynne & Dawn Joyce | July 31, 2018
A breakdown of all of the key provisions in the House-passed opioid package. From the intro: "After months of debate, the US House of Representatives passed a package of bills on June 22 addressing the opioid epidemic by a vote of 396 to 14. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT), incorporates dozens of House bills. ...
+ Read More

Medicare’s Hospital Outpatient Prospective Payment System Proposed Rule: Big Changes For 2019

By Billy Wynne | July 27, 2018
CEO Billy Wynne's breakdown of the key policy changes described in the CY19 Medicare Hospital Outpatient Prospective Payment System proposed rule....
+ Read More
Load More

Make Health Policy Work for You

Schedule a Quick Consultation
Subscribe to Our Free Newsletter